{"article_title": "Biosimilars Could Cost Patients More Than Reference Product", "article_keywords": ["product", "reference", "outofpocket", "biosimilars", "beneficiaries", "costs", "patients", "cost", "products", "report", "medicare", "biosimilar", "higher"], "article_url": "https://morningconsult.com/alert/biosimilars-could-cost-patients-more-than-reference-product/", "article_text": "Patients may pay more for biosimilar drugs than they would the original product, according to a report out today from Avalere Health, an independent consulting firm.\n\nBiosimilars, like generics, are expected to be less expensive than the primary innovator product. But higher out-of-pocket costs under Medicare Part D could discourage beneficiaries from using biosimilars, the report says.\n\nAvalere suggests requiring manufacturer discounts to close the coverage gap for biosimilars and creating a biosimilar tier that would reduce beneficiary costs for biosimilars to the same level as the reference products as policy solutions.\n\n\u201cThe unintended consequence of the ACA is that consumers have a financial disincentive to switch to a lower-cost biosimilar,\u201d Caroline Pearson, senior vice president at Avalere, said in a statement. \u201cWhile the Medicare program will save money if beneficiaries take biosimilars, higher consumer out-of-pocket costs are a barrier to patient adoption.\u201d\n\nThe Food and Drug Administration has so far approved two biosimilar products for use.", "article_metadata": {"msapplication-config": "/icons/browserconfig.xml", "viewport": "width=device-width, initial-scale=1", "og": {"site_name": "Morning Consult", "description": "Patients may pay more for biosimilar drugs than they would the original product, according to a report out today from Avalere Health, an independent consulting firm. Biosimilars, like generics, are expected to be less expensive than the primary innovator product. But higher out-of-pocket costs under Medicare Part D could discourage beneficiaries from using biosimilars, the... read more", "title": "Biosimilars Could Cost Patients More Than Reference Product - Morning Consult", "locale": "en_US", "image": "https://morningconsult.com/wp-content/themes/morning-consult/img/MC_logo_twitter_fb.png", "url": "https://morningconsult.com/alert/biosimilars-could-cost-patients-more-than-reference-product/", "type": "article"}, "twitter": {"description": "Patients may pay more for biosimilar drugs than they would the original product, according to a report out today from Avalere Health, an independent consulting firm. Biosimilars, like generics, are expected to be less expensive than the primary innovator product. But higher out-of-pocket costs under Medicare Part D could discourage beneficiaries from using biosimilars, the... read more", "creator": "@melmcintire", "image": "https://morningconsult.com/wp-content/themes/morning-consult/img/MC_logo_twitter_fb.png", "title": "Biosimilars Could Cost Patients More Than Reference Product - Morning Consult", "site": "@morningconsult", "card": "summary"}, "msapplication-TileColor": "#2b5797", "msapplication-TileImage": "/icons/mstile-144x144.png", "article": {"publisher": "https://www.facebook.com/Morning-Consult-183517831660100/", "section": "Health"}, "theme-color": "#ffffff"}, "_id": "\"57477af46914bd0286fdd853\"", "article_summary": "But higher out-of-pocket costs under Medicare Part D could discourage beneficiaries from using biosimilars, the report says.\nPatients may pay more for biosimilar drugs than they would the original product, according to a report out today from Avalere Health, an independent consulting firm.\nBiosimilars, like generics, are expected to be less expensive than the primary innovator product.\nAvalere suggests requiring manufacturer discounts to close the coverage gap for biosimilars and creating a biosimilar tier that would reduce beneficiary costs for biosimilars to the same level as the reference products as policy solutions.\n\u201cWhile the Medicare program will save money if beneficiaries take biosimilars, higher consumer out-of-pocket costs are a barrier to patient adoption.\u201dThe Food and Drug Administration has so far approved two biosimilar products for use."}